Lumos Pharma (LUMO)
(Delayed Data from NSDQ)
$1.76 USD
-0.04 (-2.22%)
Updated Jul 29, 2024 03:58 PM ET
After-Market: $1.79 +0.03 (1.70%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Lumos Pharma, Inc [LUMO]
Reports for Purchase
Showing records 21 - 40 ( 77 total )
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Clinical Collaboration with Massachusetts General Hospital for LUM-201 in Nonalcoholic Fatty Liver Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Phase 2 OraGrowtH210 Trial of LUM-201 Reaches 50% Randomization Milestone; Interim Data by YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
4Q21 Results; Interim Data From OraGrowtH210 and OraGrowtH212 Expected by YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
3Q21 Results; A Growing Opportunity for Patients with PGHD; Raising PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
2Q21 Results; Majority of Sites Open for OraGrowtH210 Trial; Cash Runway Through Important Data Readouts
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Timing of Phase 2 Data for LUM-201 Pushed Back; Lowering PT to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E